Face atopic dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinib
- 23 September 2021
- journal article
- letter
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (2) , E150-E152
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinibDrugs in Context, 2020
- Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trialJournal of Allergy and Clinical Immunology, 2020
- Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case seriesBritish Journal of Dermatology, 2019
- Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia AreataDermatology and Therapy, 2019
- Dupilumab for treatment of atopic dermatitisExpert Review of Clinical Pharmacology, 2018
- Atopic Dermatitis: Pathophysiology2017